Arcellx(ACLX)

REDWOOD CITY, CABiotechnology1 H-1B visas (FY2023)

Focus: Arcellx is a publicly traded biotechnology company focused on adaptive immune cell therapies for oncology, headquartered in Redwood City, CA. The company was acquired by Gilead for $7.8 billion in April 2026.

Oncology

Profile data last refreshed 5h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Arcellx

AI assessmentNot Hiring

No open roles listed right now. Follow Arcellx to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$110M

Pipeline & Clinical Trials

SPRX002

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT05457010Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Phase 1

Help build intelligence for Arcellx

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering CAR-T and adaptive cell therapy platform with active Phase 1/2 programs in AML and multiple myeloma
Public company with $110M in FY2025 revenue and significant R&D investment ($134M in FY2025) backing clinical development
Now integrated into Gilead's cell therapy division, providing access to a large pharma infrastructure and resources

Watch Out For

Company underwent massive workforce reduction post-Gilead acquisition, with 192 jobs eliminated at Redwood City and Rockville sites (May 2026)
Early-stage pipeline with only 2 Phase 1 trials active and no Phase 3 programs; limited near-term revenue catalysts and high cash burn ($134M R&D against $110M revenue)

Generated by Claude from Arcellx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

ARC-T Cells

Acute Myeloid Leukemia

Phase 1

anitocabtagene-autoleucel

Relapsed and Refractory Multiple Myeloma

Phase 1

anitocabtagene autoleucel

Autoimmune

Phase 1

Clinical Trials (1)

NCT06626919A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Phase 1

anitocabtagene-autoleucel

Multiple Myeloma

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Immunology, Neurology, Oncology

H-1B (2023): 1 approval

Publications: 18 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Immunology

1 pipeline

Neurology

1 pipeline

Oncology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$110M0%

R&D Spend

$134M(121%)11%

Net Income

-$71M

Cash

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

Gilead eliminated approximately 192 jobs at Arcellx's Redwood City and Rockville sites immediately following acquisition closure in May 2026, representing significant workforce disruption.

Recent mass layoffs and acquisition integration present acute employment risk; internal restructuring may continue as Gilead consolidates redundant functions and reallocates resources.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.

Expert review of hematology

2026

PMID:42269717

Targeting T-Cells for Cancer Treatment: Current Clinical Strategies and Challenges.